Evercore ISI analyst Liisa Bayko maintained a Buy rating on Innate Pharma (IPHA – Research Report) today and set a price target of $5.00.

Sarah Bianchi, Evercore ISI chief strategist of public policy, joins CNBC's 'The Exchange' to discuss the so-called DOGE ...

Evercore ISI analyst Gavin Clark-Gartner initiated coverage with a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report) today and ...

Capri and Tapestry have mutually agreed to terminate their planned merger. Capri CEO continues to see long-term potential in ...

Krishna Guha, Evercore ISI vice chairman, joins CNBC's 'Squawk Box' to discuss expectations for PPI, how a new Trump ...

Evercore ISI revised its ratings for several industrial and machinery stocks following the US election results, citing a more optimistic business outlook tied to the anticipated "pro-business Trump" ...

‘Trump trades’ move into overdrive as Dow, dollar and bond yields soar. What’s next for markets. Wall Street believes stocks will keep climbing on Trump victory — but here’s what could potentially ...

The US stocks rally is nowhere near done, according to Evercore ISI strategists, who see Donald Trump’s plans to slice through red tape propelling the S&P 500 Index another 11% through the middle of ...

The stock market is rallying heading into an election that was too close to call and might even be contested. But it makes a ...

During the third quarter of this year, total soft drink volumes grew 1.3% from a year ago, according to data from Evercore ...

Microsoft reported earnings after the close of trading Wednesday, beating with its results but forecasting a slowdown in its ...

We recently compiled a list of the 10 Best S&P 500 Stocks to Buy According to Hedge Funds. In this article, we are going to ...